Gelteq Limited executives will attend the Benchmark Company Conference for investor meetings on December 11, 2024, in New York.
Quiver AI Summary
Gelteq Limited, a company specializing in gel-based delivery solutions for various products, announced that its Co-Founders, CEO Nathan Givoni and Executive Chairman Simon Szewach, will participate in the Benchmark Company 13th Annual Discovery Investor Conference on December 11, 2024, at the New York Athletic Club. They will be available for one-on-one meetings with analysts and investors throughout the event. Gelteq, headquartered in Melbourne, Australia, aims to improve drug delivery methods in several sectors, including pharmaceuticals, nutraceuticals, and pet care, by addressing common issues like swallowing difficulties and taste. Interested investors can register to attend the conference and are encouraged to schedule meetings through their Benchmark Company representatives.
Potential Positives
- Participation in a notable investor conference demonstrates Gelteq's commitment to engaging with the investment community, which may enhance visibility and attract potential investors.
- Hosting one-on-one meetings with analysts and investors signifies Gelteq's proactive approach in fostering relationships and communicating their business strategy and growth potential.
- The involvement of key executives, including the CEO and Executive Chairman, underscores the company's leadership dedication to stakeholder engagement and transparency.
- By focusing on innovative gel-based delivery solutions that tackle common issues in drug delivery, Gelteq positions itself within growing markets, potentially appealing to a broader range of investors interested in health and wellness sectors.
Potential Negatives
- Participation in the conference may suggest a need for external investment or support, indicating potential financial instability or lack of sufficient internal resources.
- The focus on "one-on-one meetings" could imply challenges in attracting broader investor interest at the event, highlighting potential issues with public perception or confidence in the company's prospects.
- While the press release outlines the company's products and innovations, it lacks concrete details about recent business performance or milestones, leaving investors with unanswered questions regarding the company's growth and success.
FAQ
What is Gelteq Limited focused on?
Gelteq Limited specializes in developing and commercializing gel-based delivery solutions for prescription drugs, nutraceuticals, and pet care products.
When is the Benchmark Company 13th Annual Discovery Investor Conference?
The conference will be held on Wednesday, December 11, 2024, at the New York Athletic Club in New York City.
Who will represent Gelteq at the Investor Conference?
Gelteq's Co-Founders, CEO Mr. Nathan Givoni and Executive Chairman Mr. Simon Szewach, will represent the company at the conference.
How can investors schedule a meeting with Gelteq executives?
Investors should contact their Benchmark Company representative to schedule one-on-one meetings with Gelteq executives.
What are Gelteq's core areas of focus?
Gelteq focuses on five core verticals: pharmaceuticals, OTC medications, nutraceuticals, animal medications, and sports nutrition.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces that its Co-Founders, CEO Mr. Nathan Givoni and Executive Chairman Mr. Simon Szewach, will be participating in the Benchmark Company 13 th Annual Discovery Investor Conference being held on Wednesday, December 11, 2024, at the New York Athletic Club in New York City.
Mr. Givoni and Mr. Szewach will be hosting one-on-one meetings with analysts and investors throughout the day. To schedule a one-on-one meeting with them, attendees should contact their Benchmark Company representative. Investors can attend the conference by registering here .
About Gelteq Inc .
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. Gelteq is focused on advancing and commercializing its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. Gelteq’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit www.gelteq.com .
Contact:
CORE IR
516-222-2560
PR@gelteq.com
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/Chipset%20held%20over%20rush%20hour%20traffic%20by%20Jae%20Young%20Ju%20via%20iStock.jpg)
